University of Glasgow
Professor Joanne Edwards obtained a BSc in Pharmacology from the University of Glasgow followed by her PhD in Cancer Biology from the University of St Andrews. She became a Fellow of the Royal College of Pathologists in 2012 (published works). Her scientific career has included working as a Clinical Scientist in Glasgow Royal Infirmary, followed by a Senior Lecture in the Institute of Cancer Sciences University of Glasgow and more recently in January this year became a Professor of Translational Cancer Pathology. Her research portfolio focuses on investigation of signal transduction mechanisms associated with the development and progression of breast, colorectal and prostate cancer. Her aim is to identify clinically relevant aberrations in the human solid tumours and establish if they can be employed in clinical practise to improve patient care and outcome.
Role of IKK alpha in Breast Cancer
Triple negative breast cancer (TNBC) is the most aggressive subtype of breast carcinoma with limited therapeutic options. IKKα, the main catalytic kinase in the NF-κB non-canonical pathway, may be a novel therapeutic target for treatment of TNBC as elevated levels of phosphorylated IKKα in TNBC specimens is associated with reduced cancer specific survival and treatment of TNBC cell lines with IKKα inhibitors results in reduced cell viability.
EVEN MORE SEMINARS
Dr Natalie Cook University of Manchester/Christie NHS Foundation Trust
Early phase trial options in prostate cancer
Professor Noel Clarke The Christie and Salford Royal Hospitals, Manchester UK
Improving Prostate Cancer Outcomes Through Cancer Trials
Dr Qamar Ghafoor University Hospital Birmingham
Stereotactive Radiotherapy Treatment for Primary Lung Cancers, and Oligometastasis to the Lungs.
Professor Anthony Howell The University of Manchester / The Christie NHS Foundation Trust
Improving risk estimation of breast cancer
Dr Abeer Shabaan Queen Elizabeth Hospital Birmingham & University of Birmingham
Breast Pathology: Assessing tumour response to neoadjuvant chemotherapy and endocrine therapy– Pathological considerations